Bone Biologics receives Notice of Allowance of patent claims that protects formation of cartilage by UCB-1

Bone Biologics, Inc. announced today that it has received a US Patent Office Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1).  Additional claims cover the surgical application of the NELL 1 (UCB-1) protein by several delivery agents.

Bone Biologics has been developing the protein as a platform technology since 2004, leveraging the previous ten years of research in the lab performed by the company's founding scientists at UCLA.  The mechanism of action is not only identified as to how it works, but why, through this exhaustive research effort.  

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.

The patent broadly protects the formation or repair of cartilage when applying a NELL-1 sequence of UCB-1 in a region where cartilage formation or repair is desired to include the method of application comprising a variety of delivery agents in surgical applications.  

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. credited the company's partner, the Musculoskeletal Transplant Foundation (MTF) for its ongoing financial and strategic support. "MTF is essential to our progress toward realizing the full potential of the UCB-1 protein as a platform technology."

"We are pleased to continue our partnership with Bone Biologics," noted Bruce Stroever, CEO of MTF. "This latest patent issuance is a clear sign that the company is continuing to make very good progress toward FDA approval and commercialization of an important product."

SOURCE Bone Biologics, Inc.